89,447 Shares in Delcath Systems, Inc. (NASDAQ:DCTH) Acquired by Principal Financial Group Inc.

Principal Financial Group Inc. purchased a new stake in Delcath Systems, Inc. (NASDAQ:DCTH) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 89,447 shares of the company’s stock, valued at approximately $808,000.

Other hedge funds have also recently made changes to their positions in the company. Levin Capital Strategies L.P. boosted its stake in Delcath Systems by 12.2% during the first quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company’s stock valued at $262,000 after buying an additional 5,969 shares during the period. Marshall Wace LLP boosted its position in shares of Delcath Systems by 7.0% during the 2nd quarter. Marshall Wace LLP now owns 92,731 shares of the company’s stock valued at $776,000 after acquiring an additional 6,066 shares during the last quarter. Riverwater Partners LLC bought a new stake in shares of Delcath Systems during the 3rd quarter valued at about $161,000. AIGH Capital Management LLC grew its holdings in shares of Delcath Systems by 1.7% during the second quarter. AIGH Capital Management LLC now owns 2,399,792 shares of the company’s stock worth $20,086,000 after purchasing an additional 40,064 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Delcath Systems in the second quarter worth approximately $370,000. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Delcath Systems Stock Performance

Shares of DCTH opened at $9.76 on Friday. Delcath Systems, Inc. has a fifty-two week low of $2.60 and a fifty-two week high of $12.88. The firm has a market cap of $312.07 million, a price-to-earnings ratio of -7.23 and a beta of 0.75. The firm has a 50 day moving average price of $9.68 and a 200-day moving average price of $8.64.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on DCTH. Stephens reiterated a “buy” rating on shares of Delcath Systems in a research report on Friday, October 18th. StockNews.com raised shares of Delcath Systems from a “sell” rating to a “hold” rating in a report on Friday, October 25th. HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Delcath Systems in a research note on Monday, November 11th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $21.00 price target on shares of Delcath Systems in a research note on Friday, October 18th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $21.50.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.